Trial reportCardiovascular & hematological agents in medicinal chemistry2026
Comparative Efficacy and Safety of Dabigatran, Enoxaparin, and Rivaroxaban for Prophylaxis of Cancer-associated Venous Thromboembolism: A Single-center Randomized Trial.
Trial report in Cardiovascular & hematological agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe objective of this study was to compare the prophylactic efficacy of enoxaparin, dabigatran, and rivaroxaban in ambulatory patients with cancer.
methodsIn this randomized trial, patients were assigned to three groups: Group 1 received subcutaneous enoxaparin 40 mg daily (n = 35), Group 2 received oral dabigatran 150 mg daily (n = 11), and Group 3 received oral rivaroxaban 10 mg daily (n = 11) for a duration of three months. The primary outcomes were the incidence of Venous Thromboembolism (VTE) and bleeding events.
resultsThe incidence of VTE was 2 (3.5%) in patients receiving enoxaparin and 1 (1.7%) in those receiving dabigatran (P > 0.05). No thromboembolic events were reported in patients administered rivaroxaban. One patient (1.7%) in the enoxaparin group experienced a major bleeding episode (P > 0.05), while no major bleeding events were observed in patients receiving dabigatran or rivaroxaban. DISCUSSION: Enoxaparin, dabigatran, and rivaroxaban are widely used for the prevention of VTE in patients with cancer. Although some previous studies have reported differences in bleeding and VTE risk, the present study did not demonstrate significant differences among enoxaparin, dabigatran, and rivaroxaban in VTE prevention. Notably, the risk of VTE is substantially influenced by the type of cancer, the modalities of anticancer treatment, and the patient's clinical status.
conclusionThe efficacy and safety of enoxaparin, dabigatran, and rivaroxaban for the prevention of VTE in patients with cancer appear to be comparable.
Indexed as
Identifiers
41941308What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.